TY - JOUR
T1 - Intermittent treatment with droperidol, a short-acting neuroleptic, increases behavioral dopamine receptor sensitivity.
AU - Belmaker, R. H.
AU - Elami, A.
AU - Bannet, J.
PY - 1985/1/1
Y1 - 1985/1/1
N2 - Drug holidays have been proposed as a preventive strategy against the development of tardive dyskinesia. Three animal studies in which dopamine receptor hypersensitivity after chronic neuroleptic treatment was used as a model for tardive dyskinesia failed to find any reduction in dopamine receptor hypersensitivity with intermittent, as opposed to continuous, treatment. Since most neuroleptics have a long half-life in vivo, we hypothesized that truly drug-free periods may not have been achieved in previous studies. Droperidol, an ultrashort-acting butyrophenone neuroleptic, was administered to rats for 22 days in twice-daily injections or one injection every 48 hours. At 60 hours after the last dose there was no difference in apomorphine-induced stereotypy between continuously treated and intermittently treated animals. Thus, even totally drug-free periods do not reduce the development of dopamine receptor hypersensitivity.
AB - Drug holidays have been proposed as a preventive strategy against the development of tardive dyskinesia. Three animal studies in which dopamine receptor hypersensitivity after chronic neuroleptic treatment was used as a model for tardive dyskinesia failed to find any reduction in dopamine receptor hypersensitivity with intermittent, as opposed to continuous, treatment. Since most neuroleptics have a long half-life in vivo, we hypothesized that truly drug-free periods may not have been achieved in previous studies. Droperidol, an ultrashort-acting butyrophenone neuroleptic, was administered to rats for 22 days in twice-daily injections or one injection every 48 hours. At 60 hours after the last dose there was no difference in apomorphine-induced stereotypy between continuously treated and intermittently treated animals. Thus, even totally drug-free periods do not reduce the development of dopamine receptor hypersensitivity.
UR - http://www.scopus.com/inward/record.url?scp=0021904398&partnerID=8YFLogxK
U2 - 10.1007/978-3-642-70140-5_24
DO - 10.1007/978-3-642-70140-5_24
M3 - Article
AN - SCOPUS:0021904398
SN - 0179-8456
VL - 2
SP - 194
EP - 199
JO - Psychopharmacology. Supplementum
JF - Psychopharmacology. Supplementum
ER -